Study drug combo for advanced lung cancer with specific gene results
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 75 when you sign consent
- Your lung cancer is confirmed as non-small cell lung cancer (NSCLC)
- Your tumor tests match one of these groups: EGFR wild-type with no ALK gene fusion (with 0 or up to 1 prior chemotherapy), or EGFR-activating mutation after failing EGFR tablet therapy, and ALK gene fusion is negative
- You can provide fresh or stored (archival) tumor tissue for biomarker testing
- You have at least one measurable tumor spot that can be tracked; skin-only or bone-only spots do not count
- You are well enough to participate (ECOG 0–1) and have adequate blood, organ, and bone marrow function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two medications (SKB264 and anlotinib) for people with advanced non-small cell lung cancer that has spread to the liver and no longer responds to a standard pill called an EGFR-TKI. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests a new combination of an investigational drug (SPGL008) with another therapy (SSGJ-706), with or without chemotherapy, for people with advanced non-small cell lung cancer that has not spread beyond the lungs or has spread to nearby areas. The goal is to see if this combination can help control the cancer.
This trial tests a new drug (RC148) plus chemotherapy against another drug (Tislelizumab) plus chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer that has spread or can't be removed. It's for those who haven't had treatment for advanced disease yet.
This Phase 2 trial studies treatment strategies for people with stage IV non-small cell lung cancer (NSCLC) who have certain cancer gene mutations (like EGFR, ALK, or ROS1). It aims to see how different treatments affect survival and tumor response.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.